NASDAQ:PRAHPRA Health Sciences Stock Price, Forecast & News

$111.86

+3.06 (+2.81 %)

(As of 06/5/2020 12:53 PM ET)

Add

Compare

Today's Range

$110.50

Now: $111.86▼

$113.32

50-Day Range

$84.00

MA: $92.94▼

$109.50

52-Week Range

$58.67

Now: $111.86▼

$113.10

Volume231,191 shs

Average Volume439,073 shs

Market Capitalization$7.13 billion

P/E Ratio30.85

Dividend YieldN/A

Beta1.09

PRA Health Sciences, Inc., a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services. It also provides strategic solutions, such as embedded, functional services provider, staff augmentation, and custom-built development solutions, as well as commercialization services; and early development services for Phase I and Phase IIa studies, and bioanalytical analysis. The Data Solutions segment offers data, analytics, technology, and consulting solutions to the life sciences market. Its services include market intelligence services, such as targeting and compensation, and pharmaceutical audit suite services; consulting and services comprising brand analytics, managed markets, commercial effectiveness, and scientific studies/clinical hubs; and technology-enabled products and services. PRA Health Sciences, Inc. conducts clinical trials in the areas of pharmaceutical development, including oncology, immunology, central nervous system, inflammation, respiratory, cardio metabolic, and infectious diseases. The company was formerly known as PRA Global Holdings, Inc. and changed its name to PRA Health Sciences, Inc. in July 2014. PRA Health Sciences, Inc. was founded in 1976 and is headquartered in Raleigh, North Carolina.

Beat the Market (BTM) Rank^™

2.2 Analyst's Opinion

Consensus Rating
PRA Health Sciences has received a consensus rating of Hold. The company's average rating score is 2.42, and is based on 5 buy ratings, 7 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $101.00, PRA Health Sciences has a potential downside of 9.7% from its current price of $111.86.
Amount of Analyst Coverage
PRA Health Sciences has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.6 Community Rank

Outperform Votes
PRA Health Sciences has received 360 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
PRA Health Sciences has received 331 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
PRA Health Sciences has received 52.10% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about PRA Health Sciences and other stocks. Vote “Outperform” if you believe PRAH will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PRAH will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
PRA Health Sciences does not currently pay a dividend.
Dividend Growth
PRA Health Sciences does not have a long track record of dividend growth.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, PRA Health Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $323,026.00 in company stock.
Percentage Held by Insiders
Only 1.30% of the stock of PRA Health Sciences is held by insiders.
Percentage Held by Institutions
98.27% of the stock of PRA Health Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3 Earnings and Valuation

Earnings Growth
Earnings for PRA Health Sciences are expected to grow by 34.60% in the coming year, from $3.67 to $4.94 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of PRA Health Sciences is 30.85, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 16.35.
Price to Earnings Ratio vs. Sector
The P/E ratio of PRA Health Sciences is 30.85, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 29.52.
Price to Book Value per Share Ratio
PRA Health Sciences has a P/B Ratio of 6.49. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.41 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Commercial physical research

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:PRAH

Previous Symbol

CUSIPN/A

CIK1613859

Webwww.prahs.com

Phone919-786-8200

Debt

Debt-to-Equity Ratio1.30

Current Ratio0.93

Quick Ratio0.93

Price-To-Earnings

Trailing P/E Ratio30.85

Forward P/E Ratio30.48

P/E GrowthN/A

Sales & Book Value

Annual Sales$3.07 billion

Price / Sales2.32

Cash Flow$7.10 per share

Price / Cash Flow15.75

Book Value$17.23 per share

Price / Book6.49

Profitability

EPS (Most Recent Fiscal Year)$4.80

Net Income$243.02 million

Net Margins7.66%

Return on Equity27.59%

Return on Assets8.39%

Miscellaneous

Employees17,500

Outstanding Shares63,720,000

Market Cap$7.13 billion

Next Earnings Date7/29/2020 (Estimated)

OptionableOptionable

Receive PRAH News and Ratings via Email

Sign-up to receive the latest news and ratings for PRAH and its competitors with MarketBeat's FREE daily newsletter.

PRA Health Sciences (NASDAQ:PRAH) Frequently Asked Questions

How has PRA Health Sciences' stock been impacted by COVID-19 (Coronavirus)?

PRA Health Sciences' stock was trading at $88.68 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, PRAH shares have increased by 26.1% and is now trading at $111.8550. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of PRA Health Sciences?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PRA Health Sciences in the last year. There are currently 7 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for PRA Health Sciences.

When is PRA Health Sciences' next earnings date?

PRA Health Sciences is scheduled to release its next quarterly earnings announcement on Wednesday, July 29th 2020. View our earnings forecast for PRA Health Sciences.

How were PRA Health Sciences' earnings last quarter?

PRA Health Sciences Inc (NASDAQ:PRAH) posted its quarterly earnings results on Thursday, April, 30th. The medical research company reported $1.05 earnings per share for the quarter, topping analysts' consensus estimates of $1.01 by $0.04. The medical research company had revenue of $783.71 million for the quarter, compared to analysts' expectations of $749.61 million. PRA Health Sciences had a return on equity of 27.59% and a net margin of 7.66%. The company's revenue for the quarter was up 8.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.10 earnings per share. View PRA Health Sciences' earnings history.

What guidance has PRA Health Sciences issued on next quarter's earnings?

PRA Health Sciences updated its second quarter earnings guidance on Thursday, April, 30th. The company provided EPS guidance of $0.75-0.90 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.91. The company issued revenue guidance of $705-740 million, compared to the consensus revenue estimate of $666.91 million.

What price target have analysts set for PRAH?

12 analysts have issued 1-year price targets for PRA Health Sciences' stock. Their forecasts range from $82.00 to $120.00. On average, they expect PRA Health Sciences' stock price to reach $101.00 in the next year. This suggests that the stock has a possible downside of 9.7%. View analysts' price targets for PRA Health Sciences.

Has PRA Health Sciences been receiving favorable news coverage?

Media stories about PRAH stock have trended somewhat positive on Friday, InfoTrie reports. The research group identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. PRA Health Sciences earned a news impact score of 1.6 on InfoTrie's scale. They also assigned media coverage about the medical research company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news aboutPRA Health Sciences.

Who are some of PRA Health Sciences' key competitors?

Some companies that are related to PRA Health Sciences include Incyte (INCY), EXACT Sciences (EXAS), PPD (PPD), Charles River Laboratories Intl. (CRL), Icon (ICLR), Exelixis (EXEL), Syneos Health (SYNH), BTG (BTGGF), Medpace (MEDP), National Research (NRC), Precigen (PGEN), STARPHARMA HOLD/S (SPHRY), Anavex Life Sciences (AVXL), Luna Innovations (LUNA) and Auxly Cannabis Group (CBWTF). View all competitors.

What other stocks do shareholders of PRA Health Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PRA Health Sciences investors own include Alibaba Group (BABA), NVIDIA (NVDA), Adobe (ADBE), Applied Materials (AMAT), Veeva Systems (VEEV), Walt Disney (DIS), Paypal (PYPL), Home Depot (HD), Lam Research (LRCX) and UnitedHealth Group (UNH).

Who are PRA Health Sciences' key executives?

PRA Health Sciences' management team includes the following people:

Mr. Colin Shannon, Chairman, CEO & Pres (Age 60)
Mr. Michael J. Bonello, Exec. VP, CFO & Corp. Sec. (Age 49)
Mr. Kent Thoelke, Exec. VP & Chief Scientific Officer
Mr. Thomas Byrne, VP of Legal Affairs
Christine Rogers, Director of PR & Corp. Communications

When did PRA Health Sciences IPO?

(PRAH) raised $306 million in an initial public offering on Thursday, November 13th 2014. The company issued 17,000,000 shares at a price of $18.00 per share. Jefferies, Citigroup, KKR, UBS Investment Bank, Credit Suisse and Wells Fargo Securities acted as the underwriters for the IPO and Baird and William Blair were co-managers.

What is PRA Health Sciences' stock symbol?

PRA Health Sciences trades on the NASDAQ under the ticker symbol "PRAH."

Who are PRA Health Sciences' major shareholders?

PRA Health Sciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (9.87%), Wellington Management Group LLP (8.99%), Capital Research Global Investors (5.19%), Massachusetts Financial Services Co. MA (4.22%), Janus Henderson Group PLC (3.08%) and State Street Corp (2.33%). Company insiders that own PRA Health Sciences stock include Fund Holdings LP Kkr, Michael J Bonello and Pra Investors LP Kkr. View institutional ownership trends for PRA Health Sciences.

Which institutional investors are selling PRA Health Sciences stock?

PRAH stock was sold by a variety of institutional investors in the last quarter, including Invesco Ltd., Strs Ohio, BlackRock Inc., Virginia Retirement Systems ET AL, AQR Capital Management LLC, Nuveen Asset Management LLC, Acadian Asset Management LLC, and Eagle Asset Management Inc.. Company insiders that have sold PRA Health Sciences company stock in the last year include Fund Holdings LP Kkr, and Michael J Bonello. View insider buying and selling activity for PRA Health Sciences.

Which institutional investors are buying PRA Health Sciences stock?

PRAH stock was bought by a variety of institutional investors in the last quarter, including Massachusetts Financial Services Co. MA, Capital Research Global Investors, First Trust Advisors LP, Wellington Management Group LLP, Vaughan Nelson Investment Management L.P., Fuller & Thaler Asset Management Inc., JPMorgan Chase & Co., and Federated Hermes Inc.. View insider buying and selling activity for PRA Health Sciences.

How do I buy shares of PRA Health Sciences?

Shares of PRAH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is PRA Health Sciences' stock price today?

One share of PRAH stock can currently be purchased for approximately $111.86.

How big of a company is PRA Health Sciences?

PRA Health Sciences has a market capitalization of $7.13 billion and generates $3.07 billion in revenue each year. The medical research company earns $243.02 million in net income (profit) each year or $4.80 on an earnings per share basis. PRA Health Sciences employs 17,500 workers across the globe.

What is PRA Health Sciences' official website?

The official website for PRA Health Sciences is www.prahs.com.

How can I contact PRA Health Sciences?

PRA Health Sciences' mailing address is 4130 PARKLAKE AVENUE SUITE 400, RALEIGH NC, 27612. The medical research company can be reached via phone at 919-786-8200 or via email at [email protected]

This page was last updated on 6/5/2020 by MarketBeat.com Staff